Gilead Sciences Stock Performance
| GILD Stock | USD 66.76 0.60 0.91% |
The company retains a Market Volatility (i.e., Beta) of 0.5, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Gilead Sciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Gilead Sciences is expected to be smaller as well. Gilead Sciences has an expected return of -0.23%. Please make sure to check out Gilead Sciences treynor ratio, accumulation distribution, price action indicator, as well as the relationship between the potential upside and day median price , to decide if Gilead Sciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Gilead Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's essential indicators remain rather sound which may send shares a bit higher in May 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 0.91 | Five Day Return (2.21) | Year To Date Return (19.80) | Ten Year Return (6.76) | All Time Return 10.4 K |
Forward Dividend Yield 0.0466 | Payout Ratio 0.429 | Last Split Factor 2:1 | Forward Dividend Rate 3.08 | Dividend Date 2024-03-28 |
1 | AbTherx Appoints Jessica Stark, PhD, as Scientific Advisor | 03/20/2024 |
2 | Acquisition by Andrew Dickinson of 3025 shares of Gilead Sciences subject to Rule 16b-3 | 03/27/2024 |
| Gilead Sciences dividend paid on 28th of March 2024 | 03/28/2024 |
3 | Opthea appoints new director and audit chair | 04/03/2024 |
4 | Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024 | 04/08/2024 |
5 | Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 | 04/09/2024 |
6 | Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 | 04/10/2024 |
7 | Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer | 04/11/2024 |
8 | Gilead Sciences Stock Moves -0.84 percent What You Should Know | 04/12/2024 |
9 | Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq | 04/15/2024 |
10 | Aqtual Announces Appointment of Medical, Translational Research and Data Integrity Executives | 04/16/2024 |
11 | GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TW... | 04/17/2024 |
12 | Hepion ends Phase 2 study for NASH drug due to cash restraints | 04/19/2024 |
| Begin Period Cash Flow | 5.4 B | |
| Total Cashflows From Investing Activities | -2.3 B |
Gilead |
Gilead Sciences Relative Risk vs. Return Landscape
If you would invest 7,763 in Gilead Sciences on January 21, 2024 and sell it today you would lose (1,087) from holding Gilead Sciences or give up 14.0% of portfolio value over 90 days. Gilead Sciences is currently does not generate positive expected returns and assumes 1.0794% risk (volatility on return distribution) over the 90 days horizon. In different words, 9% of stocks are less volatile than Gilead, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Gilead Sciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Gilead Sciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Gilead Sciences, and traders can use it to determine the average amount a Gilead Sciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2128
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GILD |
Estimated Market Risk
| 1.08 actual daily | 9 91% of assets are more volatile |
Expected Return
| -0.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Gilead Sciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Gilead Sciences by adding Gilead Sciences to a well-diversified portfolio.
Gilead Sciences Fundamentals Growth
Gilead Stock prices reflect investors' perceptions of the future prospects and financial health of Gilead Sciences, and Gilead Sciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Gilead Stock performance.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.0978 | ||||
| Profit Margin | 0.21 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 99.64 B | ||||
| Shares Outstanding | 1.25 B | ||||
| Price To Earning | 359.42 X | ||||
| Price To Book | 3.72 X | ||||
| Price To Sales | 3.13 X | ||||
| Revenue | 27.12 B | ||||
| Gross Profit | 21.62 B | ||||
| EBITDA | 7.61 B | ||||
| Net Income | 5.61 B | ||||
| Cash And Equivalents | 6.14 B | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 24.99 B | ||||
| Debt To Equity | 1.30 % | ||||
| Current Ratio | 1.43 X | ||||
| Book Value Per Share | 18.32 X | ||||
| Cash Flow From Operations | 8.01 B | ||||
| Earnings Per Share | 4.50 X | ||||
| Market Capitalization | 82.5 B | ||||
| Total Asset | 62.12 B | ||||
| Retained Earnings | 16.3 B | ||||
| Working Capital | 4.8 B | ||||
| Current Asset | 1.18 B | ||||
| Current Liabilities | 104.89 M | ||||
About Gilead Sciences Performance
To evaluate Gilead Sciences Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Gilead Sciences generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Gilead Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Gilead Sciences market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Gilead's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 205.86 | 269.81 | |
| Return On Tangible Assets | 0.21 | 0.22 | |
| Return On Capital Employed | 0.18 | 0.19 | |
| Return On Assets | 0.09 | 0.1 | |
| Return On Equity | 0.25 | 0.26 |
Things to note about Gilead Sciences performance evaluation
Checking the ongoing alerts about Gilead Sciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Gilead Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Gilead Sciences generated a negative expected return over the last 90 days | |
| Over 88.0% of the company shares are owned by institutional investors | |
| On 28th of March 2024 Gilead Sciences paid $ 0.77 per share dividend to its current shareholders | |
| Latest headline from seekingalpha.com: Hepion ends Phase 2 study for NASH drug due to cash restraints |
- Analyzing Gilead Sciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Gilead Sciences' stock is overvalued or undervalued compared to its peers.
- Examining Gilead Sciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Gilead Sciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Gilead Sciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Gilead Sciences' stock. These opinions can provide insight into Gilead Sciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Dividend Share 3 | Earnings Share 4.5 | Revenue Per Share 21.728 | Quarterly Revenue Growth (0.04) |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.